Products
Vaborbactam was approved in the United States in 2017 as a fixed combination with the antibiotic meropenem (Vabomere, The Medicines Company). Meropenem belongs to the carbapenems and beta-lactam antibiotics group.
Structure and properties
Vaborbactam (C12H16BNO5S, Mr = 297.1 g/mol) is a cyclic boron compound and a boronic acid derivative. It is not a representative of the beta-lactams.
Effects
Vaborbactam inhibits beta-lactamases, which are involved in resistance of bacteria to meropenem. This makes the bacteria, and particularly those in the enterobacteria family, sensitive to the antibiotic. Vaborbactam is active against serine carbapenemases, specifically carbapenemase (KPC). Vaborbactam itself has no antibacterial properties. Sensitive pathogens include species complex, and .
Indications
In combination with meropenem for the treatment of complicated urinary tract infections.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
For complete precautions, see the drug label.
Adverse effects
The most common potential adverse effects of fixed combination with meropenem include headache, infusion site reactions, and diarrhea.